Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...

A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Father of two Cyrille Delville, 54, is the third of 50 men to take the stand in the ongoing sex trial that has shocked France ...

The union government has banned certain fixed-dose combination drugs due to concerns over safety, efficacy, and potential misuse.

These side dishes are healthy and delicious. It's a win-win!